GSK's Dovato Matches Gilead's Biktarvy in First Head-to-Head HIV Trial (VOGUE)

ViiV Healthcare presented the first randomized head-to-head data showing its 2-drug HIV regimen Dovato matches Gilead’s 3-drug Biktarvy in treatment-naïve adults. The Phase 3b VOGUE trial, presented at the 26th International AIDS Conference in Rio de Janeiro on July 28, met its non-inferiority endpoint at Week 48.

GSK, which owns 78.3% of ViiV, closed at $53.71 on July 28. Gilead (GILD) closed at $134.32. Both companies reported Q2 earnings the same week, but the VOGUE data is the competitive story for the HIV franchise.

VOGUE randomized 509 treatment-naïve adults with HIV-1 to receive either Dovato (dolutegravir/lamivudine, n=254) or Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, n=255). At Week 48, viral suppression (HIV-1 RNA below 50 copies/mL) was achieved in 89% of the Dovato arm versus 92% of the Biktarvy arm. The adjusted difference was -3 percentage points (95% CI: -8% to 2%), meeting the non-inferiority margin. Treatment was initiated before baseline resistance testing results were available, and zero treatment-emergent resistance emerged in either arm.

The trial enrolled a challenging population: 47% had viral loads at or above 100,000 copies/mL, 16% had viral loads at or above 500,000 copies/mL, and 16% had CD4+ counts below 200 cells/mm³. These are the high-risk subgroups where skeptics have questioned whether a 2-drug regimen can hold its own against a 3-drug regimen. VOGUE suggests it can.

Biktarvy generated $14.3 billion in 2025 sales for Gilead, making it the largest HIV drug in the world. Dovato brought in £2.7 billion ($3.6 billion) for ViiV in 2025. Gilead’s revenue advantage is roughly 4-to-1, but VOGUE gives ViiV the first direct evidence that fewer drugs can deliver equivalent outcomes in first-line therapy.

The argument for a 2-drug regimen is straightforward: fewer active agents mean lower long-term organ toxicity risk, a simpler daily pill, and potential cost savings for healthcare systems. The counterargument has been that 3-drug regimens offer a wider resistance barrier. VOGUE’s zero resistance result in both arms undercuts that concern, at least at 48 weeks.

Why does this matter now? Gilead and Merck are developing a once-weekly oral HIV pill combining islatravir and lenacapavir, which could shift the market toward long-acting regimens. Gilead’s lenacapavir is also advancing in twice-yearly PrEP. The HIV treatment field is moving away from daily orals, so VOGUE’s value is partly defensive: it gives Dovato a data-backed competitive position against Biktarvy while both franchises face disruption from long-acting alternatives.

The risk for GSK is that VOGUE’s 48-week data, while meeting non-inferiority, still shows a 3-point numerical gap favoring Biktarvy. Physicians who already prescribe Biktarvy may see no compelling reason to switch. The non-inferiority margin was wide enough that the trial cannot rule out a small real-world efficacy difference. Longer-term data and real-world switching studies will determine whether VOGUE actually moves prescribing patterns.

What to watch next: Gilead is expected to push back on the non-inferiority framing, emphasizing Biktarvy’s numerical edge and its longer real-world track record. The question is whether ViiV can convert VOGUE into formulary wins and new patient starts in a market where the entrenched leader has a 4-to-1 revenue advantage.

What It Means for the Trade

VOGUE is a defensive asset in a market that is about to be disrupted, and the trade sizes it accordingly. Dovato’s first-line opportunity against Biktarvy is real but grinding: a 3-point numerical gap, a wide non-inferiority margin, and eight years of Biktarvy’s real-world track record mean physicians have little reason to move — unless cost forces the issue. ViiV’s genuine opening is payer-driven: healthcare systems under budget pressure can swap a 2-drug regimen at lower cost for equivalent 48-week outcomes, and VOGUE is the evidence package that makes the tender argument possible. Watch European tender markets and US Medicaid formularies for the early read.

The strategic frame matters more than the trial. Gilead’s islatravir-lenacapavir weekly pill (with Merck) and lenacapavir’s twice-yearly PrEP expansion are moving the entire HIV field away from daily orals. VOGUE’s value is partly to keep Dovato relevant as a daily 2-drug option while ViiV’s own long-acting cabotegravir-rilpivirine franchise matures. It is trench warfare before the format war.

For GSK specifically, ViiV (78.3%-owned) is the growth engine offsetting a flattening respiratory and vaccines story; even modest Dovato share gains compound against Gilead’s HIV revenue concentration risk.

Mechanism and Market Context

The 2-drug thesis rests on dolutegravir’s resistance profile: as an integrase inhibitor with a high genetic barrier, paired with lamivudine, it achieves suppression historically requiring three agents — sparing tenofovir-associated renal and bone toxicity in patients on lifetime therapy. VOGUE’s zero treatment-emergent resistance in both arms, in a population where 47% entered above 100,000 copies/mL, is the key mechanistic validation: the objection to 2-drug regimens was always high-viremia failure risk, and the trial directly enrolled that subgroup.

The honest counterweights: non-inferiority with a 3-point deficit cannot exclude a small real efficacy gap, and 48 weeks is early for lifetime therapy. Biktarvy’s decade-scale dataset — including renal-safety experience with TAF — is not matched by any trial. Gilead’s counterargument writes itself, and the market-share fight will be decided less by slide decks than by formulary math.

Risks and What Could Go Wrong

1. Long-acting interception. If the islatravir-lenacapavir weekly pill converts prescribers in 2027, daily-regimen market share becomes a shrinking pie and VOGUE’s window closes before it pays.
2. Numerical-gap narrative. Gilead’s pushback on the 3-point difference could freeze switching behavior; doctors default to the incumbent when data looks ambiguous.
3. Cost-channel failure. If payers do not actively prefer the 2-drug option, the main commercial lever never activates.
4. ViiV franchise dependence. GSK’s growth story leans on ViiV performing while vaccines stumble; any Dovato shortfall is amplified at the parent level.

Net: solid defensive data, modest offensive value. Trade it via GSK’s ViiV contribution and the formulary-read signals, not as a Biktarvy-killer narrative.